2023年第2版《NCCN胰腺癌临床实践指南》更新解读  

Interpretation of 2023 2nd NCCN clinical practice guidelines in oncology⁃pancreatic adenocarcinoma

作　　者：陈佳浩 姜翀弋[1] CHEN Jiahao;JIANG Chongyi(Department of Hepato-Biliary-Pancreatic&Splenic Surgery,Huadong Hospital,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华东医院肝胆胰脾外科,上海200040

出　　处：《外科理论与实践》2024年第1期10-13,共4页Journal of Surgery Concepts & Practice

基　　金：国家自然科学基金(82372968);上海市申康医院发展中心项目(SHDC2024CRI080);复旦大学医学工程联合基金(XM03231533)。

摘　　要：胰腺癌是预后极差的消化系统恶性肿瘤。美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)结合最新高质量循证医学证据不断更新推出胰腺癌的临床实践指南以指导胰腺癌的规范化诊疗。2023年5月4日与6月19日《NCCN胰腺癌临床实践指南》分别进行了两次更新。相较于2022年第2版,这两次更新主要集中于最新的免疫/靶向治疗进展、NALIRIFOX方案的引入以及体能状态中等病人治疗方案的补充。本文结合相关循证医学证据对最新《NCCN胰腺癌临床实践指南》的更新进行解读。Pancreatic adenocarcinoma,a severe digestive malignancy,is characterized by its poor prognosis.The National Comprehensive Cancer Network(NCCN)persistently refines its guidelines,integrating cutting-edge evidencebased medical insights to standardize the diagnostic and therapeutic strategies of pancreatic adenocarcinoma.The NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma were updated twice on May 4 and June 19,2023,respectively.Compared to the 2022 predecessor,these two updates placed a particular emphasis on immunotherapy/targeted therapy,the introduction of NALIRIFOX regimen,and supplementary treatment protocols for patients with intermediate performance status.This article provided an interpretation of the latest updates to the NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma,integrating relevant evidence-based medical findings.

关 键 词：胰腺癌 美国国立癌症综合网络(NCCN) 指南 解读 

分 类 号：R735.9[医药卫生—肿瘤]